Ginkgo Bioworks Holdings Inc. (DNA): Technicals Say You should Hold


Ginkgo Bioworks Holdings Inc. (NYSE:DNA) saw an upside of 10.84% to close Monday at $1.84 after adding $0.18 on the day. The 5-day average trading volume is 20,081,480 shares of the company’s common stock. It has gained $2.0600 in the past week and touched a new high 2 times within the past 5 days. An average of 20,130,061 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 24,182,141.

DNA’s 1-month performance is 11.52% or $0.1800 on its low of $1.4500 reached on 01/06/23. The company’s shares have touched a 52-week low of $1.45 and high of $6.38, with the stock’s rally to the 52-week high happening on 01/18/23. YTD, DNA has achieved 8.88% or $0.1500 and has reached a new high 5 times. However, the current price is down -71.16% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Insider Transactions

DNA stock investors last saw insider trading activity on Jan 19.Kelly Jason R () most recently sold 262,193 shares at $1.70 per share on Jan 19. This transaction cost the insider $446,629. 10% Owner, Canton Barry, sold 199,843 shares at a price of $1.71 on Jan 19. Then, on Jan 19, 10% Owner Canton Barry sold 162,193 shares at a price of $1.71 per share. This transaction amounted to $277,999.

Valuation Metrics

Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 5.36 while the price-to-book (PB) in the most recent quarter is 2.09.

Ginkgo Bioworks Holdings Inc.’s quick ratio for the period ended September 29 was 11.70, with the current ratio over the same period at 11.70. As well, the company’s long term debt to equity for the quarter ending September 29 was 0.04, while the total debt to equity was 0.04. In terms of profitability, the gross margin trailing 12 months is 54.40%. The firm’s gross profit as reported stood at $184.15 million against revenue of $313.84 million.

Earnings Surprise

For the quarterly period ending September 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected DNA to announce -$0.3 per share in earnings in its latest quarter, but it posted -$0.41, representing a -36.70% surprise. EBITDA for the quarter stood at more than -$643.51 million. DNA stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 430.96 million, with total debt at $59.84 million. Shareholders hold equity totaling $1.74 billion.

Let’s look briefly at Ginkgo Bioworks Holdings Inc. (DNA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 57.09% to suggest the stock is trending Neutral, with historical volatility in this time period at 109.83%.

The stock’s 5-day moving average is $1.7980, reflecting a -1.08% or -$0.0200 change from its current price. DNA is currently trading +5.14% above its 20-day SMA, -31.09% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -27.56% and SMA200 by-49.03%.

Stochastic %K and %D was 44.81% and 51.53% and the average true range (ATR) pointed at 0.1707. The RSI (14) points at 53.37%, while the 14-day stochastic is at 63.93% with the period’s ATR at 0.1679. The stock’s 9-day MACD Oscillator is pointing at -0.0467 and 0.0269 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Ginkgo Bioworks Holdings Inc. (NYSE: DNA), Berenberg launched coverage with a Buy rating. Analysts offering their rating for DNA stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate DNA as a “sell,”, while 2 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 1 rates the stock as overweight while 5 have offered a “buy” rating.

What is DNA’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $2.00 and a high of $12.00, with their median price target at $4.00. Looking at these predictions, the average price target given by analysts is for Ginkgo Bioworks Holdings Inc. (DNA) stock is $4.93.


Please enter your comment!
Please enter your name here